Stroke is the leading cause of disability in North America and the third leading cause of death.
Health Agency of Canada and the Heart and Stroke Foundation of Canada. It represents Canadian experts in the field of hypertension and provides annual evidence-based recommendations regarding the diagnosis and treatment of hypertension. This year marks the sixth consecutive year that the CHEP has updated its guidelines.
As neurologists, we are commonly faced with patients having both cerebrovascular diseases and high blood pressure. In this article, we present the 2005 CHEP recommendations for hypertension from a stroke perspective.
METHODS
The 2005 CHEP recommendations process incorporated all trials and epidemiological observational studies published in the past 12 months relevant to hypertension. The interpretation/ impact of these studies was considered in the context of the cumulative evidence of past publications. For 2005, we incorporated the SHEAF Study, 5 the Ohasama Cohort, 6, 7 the OvA Study, 8 Staessen et al., 9 Thijs et al, 10 VALUE, 11 ACTION, 12 INVEST 13 and VALIANT, 14 as well as a range of smaller studies and systematic reviews (particularly the Blood Pressure Lowering Treatment Trialists Collaboration 15 and the calcium channel blockers meta-analysis 16 ). The CHEP guidelines are based solely on efficacy data and do not include physicians/experts preferences and cost-effectiveness analysis.
RECOMMENDATIONS

Diagnosis and technique
The diagnosis of hypertension should be expedited (Figure) .
Past guidelines required a minimum of three visits with a blood pressure (BP) > 140/90mmHg to make the diagnosis of hypertension in patients with target organ damage, including stroke or transient ischemic attack. Although minimizing the risk of misdiagnosing patients as hypertensive, such a conservative approach is not practical given the realities of health care delivery in Canada and is no longer appropriate. There is accumulating evidence that delaying treatment may expose high risk hypertensive patients to undue risk of hypertensive complications (CAPP, 17 ALLHAT, 18 VALUE 11 ). In these studies, it was suggested that early differences in secondary endpoints between treatment regimens were due to differences in the early extent of blood pressure control. It has also been shown that the risk of stroke begins to increase at a blood pressure as low as 115/75 mmHg. 16 Therefore, the 2005 recommendations necessitate only two visits in patients with target organ damage such as stroke, diabetes or chronic kidney disease. The diagnosis may still be made confidently at the first visit in those presenting with a hypertensive crisis.
Although an office-based technology is most often used by neurologists and other physicians for the diagnosis of hypertension, there is concern about the measurement of blood pressure in this setting. Patients may suffer from the "white coat hypertension", even with careful attention to technique. Patients are instructed to avoid caffeine one hour prior to and smoking 30 minutes prior to the blood pressure measurement. An appropriate cuff size is essential. Measurement should be undertaken after five minutes rest. Blood pressure should initially be evaluated in both arms and at least twice on the side with the highest value. It is now firmly established that other modalities are as, or more effective, in the measurement/evaluation and prognostic determination of blood pressure elevations, than the clinic evaluation. 
Investigations
All hypertensive patients should have baseline investigations, including: complete blood count, urinalysis, blood chemistry (creatinine, electrolytes), a fasting glucose, a fasting lipid profile and a 12-lead echocardiogram (ECG) (looking for left ventricular hypertrophy or evidence of past myocardial infarction). An echocardiogram is not recommended routinely. A renal ultrasound is performed (to exclude an obstruction, polycystic kidney disease or evaluate kidneys size) in those with increased creatinine, renal disease or proteinuria. Stroke patients with hypertension presenting with spontaneous or profound diuretic-induced hypokalemia (< 3mmol/L), refractory high blood pressure or incidental adrenal adenomas should be investigated for primary hyperaldosteronism (morning sample of plasma renin and aldosterone). Uncontrolled hypertension (≥ 3 drugs), deteriorating renal function or recurrent episodes of pulmonary edema suggest renovascular hypertension and patients should be further evaluated.
Lifestyle modifications
Lifestyle modifications are the cornerstone of the "global" management of many atherosclerotic risk factors, including hypertension (Table 2) . Modern western societies discourage physical activity resulting in an epidemic of obesity in North America. 19 Even brief physician and dietician interventions have proven beneficial in hypertensive patients. 20 Exercising 30 to 60 minutes four to seven days a week (i,e., walking) will reduce the possibility of becoming hypertensive and reduce blood pressure in those already hypertensive (as well as having beneficial effects on serum lipids). 21 Therefore, lifestyle modifications should be encouraged even before the development of hypertension in patients with stroke. A well-balanced and healthy diet, including a large quantity of fruits/vegetables and a low quantity of saturated fat is advised. 22, 23 A daily salt intake below 100mmol/L is recommended, especially in those considered saltsensitive: Canadians of African descent, patients over 45 years old, individuals with impaired renal function or with diabetes. Moderation of alcohol intake (≤ 14 drinks/week for men and ≤ 7-9 drinks/week for women) is advocated as is cessation of cigarette smoking. Keeping the waist circumference less than 102 cm for men and 88 cm for women will reduce the possibility of becoming hypertensive and developing the metabolic syndrome. 24 Each lifestyle modification is approximately as effective in reducing blood pressure as one prescribed medication. 20, 21, 23, 24 Neurologists as well as other physicians should be proactive in promoting healthy lifestyles in patients with stroke. 
LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES
Pharmacological treatment
Stroke is considered evidence of target organ damage. The targets for BP control are not specifically different for stroke patients [ Table 3 ]. Blood pressures at least lower than 140/90 mmHg should be obtained in all patients. Although some data suggest that an increased risk of stroke begins as the blood pressures rises above 115/75mmHg, 16 there has been no randomized controlled trial (in patients with stroke) aiming for blood pressure as low as 120/80mmHg or showing a benefit by reducing blood pressure to such values.
Preventing hypertension-related complications in the "general" population of patients with hypertension is more dependent on the extent of blood pressure lowering achieved than on the choice of any specified "first-line drug". Any of the five drug classes shown to reduce cardiovascular outcomes in hypertensive individuals is an appropriate choice for first line monotherapy in hypertensive patients. Thiazide diuretics, longacting calcium channel blockers, beta-blockers (in patients younger than 60 years), angiotensin converting enzyme inhibitors (ACEI) (in non-blacks), angiotensin receptor blockers (ARBs) are all acceptable first-line therapies. The new inclusion of longer-acting nondihydropyridine agents reflects the accumulating evidence, including a systematic review demonstrating the comparable effectiveness of both dihydropyridine and nondihydropyridine agents in reducing hypertension-related complications. 16 For secondary prevention in patients with stroke and hypertension, the current literature suggests that a combination of an ACE inhibitor and a thiazide diuretic is the preferred therapy. For those with contraindications, other classes of medications mentioned above may be used. Although all classes of agents have been proven efficacious in preventing stroke among hypertensive patients, only one randomized controlled trial studied exclusively a stroke population at baseline and used stroke as the primary endpoint. 25 In the PROGRESS trial, the combination ACE inhibitor/thiazide diuretic was superior to placebo while an ACE inhibitor alone showed no superiority to placebo. This study did not provide a direct comparison with other classes of agents. The Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) also included patients with stroke but the exact number was not mentioned (23% had either a stroke or a myocardial infarction at baseline) and the primary endpoint was coronary heart disease mortality/non fatal myocardial infarction. 18 In this study, the primary endpoint was not significantly different between groups. Until a direct comparison between classes of antihypertensive agents in patients with stroke is achieved, a combination of an ACE inhibitor/thiazide diuretic is recommended.
Among patients with stroke, the global cardiovascular risk should also be addressed. Therefore, statins and platelet inhibitors are complementary and essential to any antihypertensive strategy and should be considered for all. Note that the beneficial effect of statin therapy among patients who have already suffered a stroke appears largely in reducing cardiac risk rather than reducing future stroke. 26 Patients' adherence to therapy, including lifestyle modifications, is an essential component of hypertension management. Noncompliance is an important cause of "resistant" hypertension. Education of the patient and family are critical. Simple regimens (i.e once daily dosing) are preferred. It is important to assess adherence to therapy at each visit (eg. by asking patients and family about medication/life style habits, compliance/side effects, looking at drug bottle pill consumption, etc). Self measurement of blood pressure and strategies to increase self management of hypertension can be effective in improving adherence.
High blood pressure in the setting of acute stroke
High blood pressure is very common at presentation and early after ischemic (75%) or hemorrhagic (>80%) stroke. 27 In both cases, this is associated with a poor functional outcome. 28 There is a paucity of evidence-based data in the literature and therefore CHEP has not issued explicit recommendations on managing hypertension in acute stroke. Although a phase II study showed the safety of an angiotensin receptor blocker (average time of 30 hours post stroke), there was no significant reduction in blood pressure in the active treatment group. 29 The ASA/AHA (American Stroke Association/American Heart Association) recommends treating blood pressures above 220/120 mmHg for ischemic stroke and over 185/105mmHg for hemorrhagic stroke. 30, 31 The CHEP 2005 recommendations do not involve a specific blood pressure range. Because it is unclear how to proceed, a conservative approach is warranted, especially in older patients with ischemic stroke and suspected carotid In those eligible for intravenous thrombolytic therapy, a blood pressure lower than 185/110 mmHg must be obtained prior and during treatment, based on the NINDS inclusion-criteria. 32 Labetalol, being easily titrated and having minimal vasodilatory effects on cerebral vessels, is often used. Short acting calcium antagonists should be avoided because of their rapid absorption and their potential to induce acute hypotension. 33, 34 Clonidine also has the potential of substantially reducing blood pressure and should be used with caution.
Urgent trials concerning the management of high blood pressure and acute stroke are needed. This has been recognized as a priority by the International Society of Hypertension. 27 Future research should address the following questions: Should blood pressure be elevated or lowered (with target BP ranges) in patients with ischemic stroke? With hemorrhagic stroke? Which drug classes should be used? When should therapy be initiated? Which subgroups of patients benefit according to: demographics, stroke mechanism, co-morbid conditions, severity of neurological lesions and coexistent medications?
CONCLUSIONS
Hypertension is a significant public health problem in Canada and remains one of the most common and important risk factors for stroke. Blood pressure should be maintained below 140/90mmHg in most patients with stroke. A combination of an ACE inhibitor and a thiazide diuretic is suggested for secondary prevention in these patients. Lifestyle modifications remain the cornerstone of the treatment and prevention of hypertension. Neurologists should be active in the management of this condition, including prescribing medications and counseling stroke patients about their risk factors.
